AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

NHS patients risk losing access to the world’s best medicines unless the UK spends more on developing new treatments, the ...

CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere ...

Drugmakers feel empowered to resist foreign price controls — confident that the Trump administration will have their backs.

ASTRAZENECA delivered better-than-expected third quarter earnings and retained its full-year forecasts on Thursday, with strong sales of its blockbuster cancer and cardiovascular drugs.

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

Novo Nordisk and Eli Lilly said they've agreed to sell their blockbuster drugs Wegovy and Zepbound at a discount.

The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. Click to read why AZN is a Hold.

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

AstraZeneca's Q3 sales rose 12% to $15.19 billion, beating forecasts as cancer and biopharma growth lifted results; 2025 ...

The drugs are part of a new generation of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...